Depression - Pipeline Review, H2 2018

Date: September 11, 2018
Pages: 504
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: D58016CFAA6EN
Leaflet:

Download PDF Leaflet

Depression - Pipeline Review, H2 2018
Depression - Pipeline Review, H2 2018

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Depression - Pipeline Review, H2 2018, provides an overview of the Depression (Central Nervous System) pipeline landscape.

Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Signs and symptoms include sleep disturbances, including insomnia or sleeping too much, changes in appetite, anxiety, agitation or restlessness and physical problems, such as back pain or headaches. Treatment includes antidepressants, mood stabilizers or antipsychotics.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Depression - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Depression (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Depression (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Depression and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 16, 33, 30, 76, 12 and 5 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 12 and 7 molecules, respectively.

Depression (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Depression (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Depression (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Depression (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Depression (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Depression (Central Nervous System)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Depression (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Depression (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


NOTE: Out of security concerns Global Markets Direct requires using corporate email address.
Introduction
Depression - Overview
Depression - Therapeutics Development
Depression - Therapeutics Assessment
Depression - Companies Involved in Therapeutics Development
Depression - Drug Profiles
Depression - Dormant Projects
Depression - Discontinued Products
Depression - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Depression, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Universities/Institutes, H2 2018
Products under Development by Universities/Institutes, H2 2018 (Contd.1), H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Depression - Pipeline by Acadia Pharmaceuticals Inc, H2 2018
Depression - Pipeline by Ache Laboratorios Farmaceuticos SA, H2 2018
Depression - Pipeline by Adamed Sp z oo, H2 2018
Depression - Pipeline by Addex Therapeutics Ltd, H2 2018
Depression - Pipeline by Aequus Pharmaceuticals Inc, H2 2018
Depression - Pipeline by Albany Molecular Research Inc, H2 2018
Depression - Pipeline by Alkermes Plc, H2 2018
Depression - Pipeline by Allergan Plc, H2 2018
Depression - Pipeline by Amorsa Therapeutics Inc, H2 2018
Depression - Pipeline by Anavex Life Sciences Corp, H2 2018
Depression - Pipeline by Avanir Pharmaceuticals Inc, H2 2018
Depression - Pipeline by Axsome Therapeutics Inc, H2 2018
Depression - Pipeline by Azevan Pharmaceuticals Inc, H2 2018
Depression - Pipeline by BioCrea GmbH, H2 2018
Depression - Pipeline by Bionomics Ltd, H2 2018
Depression - Pipeline by BioXcel Therapeutics Inc, H2 2018
Depression - Pipeline by Blackthorn Therapeutics Inc, H2 2018
Depression - Pipeline by Boehringer Ingelheim GmbH, H2 2018
Depression - Pipeline by Bristol-Myers Squibb Co, H2 2018
Depression - Pipeline by Calico LLC, H2 2018
Depression - Pipeline by Celgene Corp, H2 2018
Depression - Pipeline by Cellix Bio Pvt Ltd, H2 2018
Depression - Pipeline by Celon Pharma SA, H2 2018
Depression - Pipeline by Cerecor Inc, H2 2018
Depression - Pipeline by Clera Inc, H2 2018
Depression - Pipeline by Delpor Inc, H2 2018
Depression - Pipeline by DURECT Corp, H2 2018
Depression - Pipeline by Eisai Co Ltd, H2 2018
Depression - Pipeline by Eli Lilly and Co, H2 2018
Depression - Pipeline by Fabre-Kramer Pharmaceuticals Inc, H2 2018
Depression - Pipeline by FPRT Bio Inc, H2 2018
Depression - Pipeline by GlaxoSmithKline Plc, H2 2018
Depression - Pipeline by GliaCure Inc, H2 2018
Depression - Pipeline by H. Lundbeck AS, H2 2018
Depression - Pipeline by Heptares Therapeutics Ltd, H2 2018
Depression - Pipeline by Impel NeuroPharma Inc, H2 2018
Depression - Pipeline by Intas Pharmaceuticals Ltd, H2 2018
Depression - Pipeline by IntelGenx Corp, H2 2018
Depression - Pipeline by Intra-Cellular Therapies Inc, H2 2018
Depression - Pipeline by Jiangsu Nhwa Pharmaceutical Corp Ltd, H2 2018
Depression - Pipeline by Johnson & Johnson, H2 2018
Depression - Pipeline by Karuna Pharmaceuticals Inc, H2 2018
Depression - Pipeline by KemPharm Inc, H2 2018
Depression - Pipeline by Kissei Pharmaceutical Co Ltd, H2 2018
Depression - Pipeline by Lead Discovery Center GmbH, H2 2018
Depression - Pipeline by Les Laboratoires Servier SAS, H2 2018
Depression - Pipeline by Lixte Biotechnology Holdings Inc, H2 2018
Depression - Pipeline by Luye Pharma Group Ltd, H2 2018

LIST OF FIGURES

Number of Products under Development for Depression, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

COMPANIES MENTIONED

Acadia Pharmaceuticals Inc
Ache Laboratorios Farmaceuticos SA
Adamed Sp z oo
Addex Therapeutics Ltd
Aequus Pharmaceuticals Inc
Albany Molecular Research Inc
Alkermes Plc
Allergan Plc
Amorsa Therapeutics Inc
Anavex Life Sciences Corp
Avanir Pharmaceuticals Inc
Axsome Therapeutics Inc
Azevan Pharmaceuticals Inc
BioCrea GmbH
Bionomics Ltd
BioXcel Therapeutics Inc
Blackthorn Therapeutics Inc
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Co
Calico LLC
Celgene Corp
Cellix Bio Pvt Ltd
Celon Pharma SA
Cerecor Inc
Clera Inc
Delpor Inc
DURECT Corp
Eisai Co Ltd
Eli Lilly and Co
Fabre-Kramer Pharmaceuticals Inc
FPRT Bio Inc
GlaxoSmithKline Plc
GliaCure Inc
H. Lundbeck AS
Heptares Therapeutics Ltd
Impel NeuroPharma Inc
Intas Pharmaceuticals Ltd
IntelGenx Corp
Intra-Cellular Therapies Inc
Jiangsu Nhwa Pharmaceutical Corp Ltd
Johnson & Johnson
Karuna Pharmaceuticals Inc
KemPharm Inc
Kissei Pharmaceutical Co Ltd
Lead Discovery Center GmbH
Les Laboratoires Servier SAS
Lixte Biotechnology Holdings Inc
Luye Pharma Group Ltd
Mapi Pharma Ltd
Mapreg SAS
MedinCell SA
Medlab Clinical Ltd
Meta-IQ ApS
Mitsubishi Tanabe Pharma Corp
Navitor Pharmaceuticals Inc
Neuralstem Inc
Neurocrine Biosciences Inc
NeuroNascent Inc
Nippon Chemiphar Co Ltd
Novartis AG
Omeros Corp
Otsuka Holdings Co Ltd
Pfizer Inc
Pherin Pharmaceuticals Inc
Protagenic Therapeutics Inc
Relmada Therapeutics Inc
Reviva Pharmaceuticals Inc
Richter Gedeon Nyrt
Sage Therapeutics Inc
Shenox Pharmaceuticals LLC
SK Biopharmaceuticals Co Ltd
Sound Pharmaceuticals Inc
Sumitomo Chemical Co Ltd
Sumitomo Dainippon Pharma Co Ltd
Sunovion Pharmaceuticals Inc
Supernus Pharmaceuticals Inc
Syntropharma Ltd
Taisho Pharmaceutical Holdings Co Ltd
Takeda Pharmaceutical Co Ltd
Trevena Inc
VistaGen Therapeutics Inc
Zysis Ltd
Skip to top


Depression - Pipeline Review, H1 2018 US$ 2,000.00 Mar, 2018 · 490 pages

Ask Your Question

Depression - Pipeline Review, H2 2018
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: